Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004.

BACKGROUND Diabetes mellitus is the leading cause of chronic kidney disease (CKD) and contributes to increased morbidity and mortality in the CKD population. Early diabetes identification through targeted screening programs is important for the development of preventive strategies. METHODS This is a cross-sectional analysis of the National Kidney Foundation Kidney Early Evaluation Program (KEEP) data and National Health and Nutrition and Examination Survey (NHANES) 1999-2004 data. KEEP is a community-based health-screening program enrolling individuals 18 years or older with diabetes, hypertension, or family history of kidney disease, diabetes, or hypertension. Study participants were those identified as meeting these inclusion criteria. Participants who had received kidney transplants or were currently receiving dialysis therapy were excluded. RESULTS Of 73,460 KEEP participants, 20,562 (28.0%) had diabetes compared with 1,545 of 17,049 (6.7%) NHANES participants. Age, obesity, high cholesterol level, hypertension, and cardiovascular disease distributions were similar for patients with diabetes in both populations, whereas women and African Americans were overrepresented in KEEP. The prevalence of diabetes in KEEP progressively increased with increasing stage of CKD, and this relationship persisted in subgroup analyses of older participants (age > 46 years), as well as in analyses stratified by sex, race, and other CKD risk factors: current tobacco use, obesity, hypertension, cardiovascular disease, and increased cholesterol level. KEEP participants with CKD who reported having diabetes were unlikely to have met target blood glucose levels (odds ratio, 0.71; 95% confidence interval, 0.66 to 0.77; P < 0.001). Reporting not having diabetes was associated with the likelihood of increased blood glucose levels (odds ratio, 1.28; 95% confidence interval, 1.16 to 1.41; P < 0.001). CONCLUSION KEEP is congruent with NHANES regarding a greater prevalence of diabetes in patients with CKD. As a targeted screening program, KEEP may represent a higher risk and more motivated patient population.

[1]  C. Jurkovitz,et al.  The Kidney Early Evaluation Program (KEEP): program design and demographic characteristics of the population. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  L. Stevens,et al.  Standardization of serum creatinine and estimated GFR in the Kidney Early Evaluation Program (KEEP). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[4]  Keith C. Norris,et al.  Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). , 2007, Archives of internal medicine.

[5]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[7]  A. Collins,et al.  Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[9]  A. Di Giorgio,et al.  Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. , 2005, Diabetes care.

[10]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[11]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[12]  J. McGill,et al.  Kidney Early Evaluation Program (KEEP) , 2004, The Diabetes educator.

[13]  J. Lane.  Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. , 2004, American journal of physiology. Renal physiology.

[14]  R. MacIsaac,et al.  New insights into the significance of microalbuminuria , 2004, Current opinion in nephrology and hypertension.

[15]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[16]  W. Keane,et al.  Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. , 2003, Kidney international. Supplement.

[17]  J. Sowers,et al.  Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. , 2002, Hypertension.

[18]  Nancy Fink,et al.  The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality , 2002, Annals of Internal Medicine.

[19]  Samy I McFarlane,et al.  Insulin resistance and cardiovascular disease. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  H. Ginsberg.  Insulin resistance and cardiovascular disease. , 2000, The Journal of clinical investigation.

[21]  M. Klag,et al.  ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease and Hypertension Early Detection of Kidney Disease in Community Settings: The Kidney Early Evaluation Program (KEEP) , 2003 .